Adenosine antagonists potentiate D2 dopamine-dependent activation of Fos in the striatopallidal pathway

Pollack, Alexia E.; Fink, J. Stephen

doi:10.1016/0306-4522(95)00168-i

Cited by 92 publications

(61 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This has been repeatedly demonstrated in a number of experimental models involving rodents pretreated with D 2 receptor antagonists, reserpine, or MPTP or after genetic inactivation of D 2 receptors Popoli et al, 1991;Kanda et al, 1994;Giménez-Llort et al, 1995;Pollack and Fink, 1995;Malec, 1997;Shiozaki et al, 1999;Ward and Dorsa, 1999;Wardas et al, 1999;Aoyama et al, 2000;Chen et al, 2001;Ferré et al, 2001;Hauber et al, 2001) and involving MPTP-treated monkeys (Kanda et al, 1998a,b;Grondin et al, 1999). The results of these experiments suggest that A 2A receptor antagonists can be useful in the treatment of Parkinson's disease.…”

Section: Interactions Between Adenosinementioning

confidence: 85%

“…In this way, the products of A 2A receptor activation are kept at low concentration under normal basal conditions and inactivation of striatal D 2 receptormediated neurotransmission (by administration of D 2 receptor antagonists, striatal dopamine depletion or genetic D 2 receptor inactivation) liberates A 2A receptormediated function from the strong D 2 receptor-mediated tonic inhibition. This results in a very significant increase in the striatal expression of c-Fos, Thr-34-phosphorylated DARPP-32, enkephalin, and neurotensin, which is partially counteracted by genetic inactivation or pharmacological blockade of A 2A receptors (Schiffman and Vanderhaeghen, 1993;Morelli et al, 1995;Pollack and Fink, 1995;Boegman and Vincent, 1996;Adams et al, 1997;Pinna et al, 1997Pinna et al, , 1999Richardson et al, 1997;Svenningsson et al, 1999aSvenningsson et al, , 2000Ward and Dorsa, 1999;Chen et al, 2000Chen et al, , 2001Zahniser et al, 2000;Dassesse et al, 2001;Ferré et al,. 2002;, see Section I.B.).…”

Section: Interactions Between Adenosinementioning

confidence: 99%

See 1 more Smart Citation

Molecular Mechanisms and Therapeutical Implications of Intramembrane Receptor/Receptor Interactions among Heptahelical Receptors with Examples from the Striatopallidal GABA Neurons

et al. 2003

View full text Add to dashboard Cite

Section: Interactions Between Adenosinementioning

confidence: 85%

Section: Interactions Between Adenosinementioning

confidence: 99%

Molecular Mechanisms and Therapeutical Implications of Intramembrane Receptor/Receptor Interactions among Heptahelical Receptors with Examples from the Striatopallidal GABA Neurons

et al. 2003

View full text Add to dashboard Cite

“…This has been shown in several experimental models including rodents pretreated with D 2 receptor antagonists, reserpine, 6-OH-dopamine or MPTP or after genetic inactivation of D 2 receptors (Kanda et al, 1994;Pollack and Fink, 1995;Shiozaki et al, 1999;Ward and Dorsa, 1999;Chen et al, 2001, Ferré et al, 2001Hauber et al, 2001;Wardas et al, 2001) or MPTP-treated monkeys (Kanda et al, 1998;Grondin et al, 1999). Reserpinized mice, rats with unilateral 6-OH-dopamine lesions and MPTP-treated monkeys are well-established validated models of Parkinson's disease.…”

Section: Adenosine a 2a Receptors In The Ventral Striatum And The Acumentioning

confidence: 92%

Adenosine A2A receptors in ventral striatum, hypothalamus and nociceptive circuitry

Ferré

Diamond

Goldberg

et al. 2007

Progress in Neurobiology

126

View full text Add to dashboard Cite

Adenosine A 2A receptors localized in the dorsal striatum are considered as a new target for the development of antiparkinsonian drugs. Co-administration of A 2A receptor antagonists has shown a significant improvement of the effects of L-DOPA. The present review emphasizes the possible application of A 2A receptor antagonists in pathological conditions other than parkinsonism, including drug addiction, sleep disorders and pain. In addition to the dorsal striatum, the ventral striatum (nucleus accumbens) contains a high density of A 2A receptors, which presynaptically and postsynaptically regulate glutamatergic transmission in the cortical glutamatergic projections to the nucleus accumbens. It is currently believed that molecular adaptations of the cortico-accumbens glutamatergic synapses are involved in compulsive drug seeking and relapse. Here we review recent experimental evidence suggesting that A 2A antagonists could become new therapeutic agents for drug addiction. Morphological and functional studies have identified lower levels of A 2A receptors in brain areas other than the striatum, such as the ventrolateral preoptic area of the hypothalamus, where adenosine plays an important role in sleep regulation. Although initially believed to be mostly dependent on A 1 receptors, here we review recent studies that demonstrate that the somnogenic effects of adenosine are largely mediated by hypothalamic A 2A receptors. A 2A receptor antagonists could therefore be considered as a possible treatment for narcolepsy and other sleep-related disorders. Finally, nociception is another adenosine-regulated neural function previously thought to mostly involve A 1 receptors. Although there is some conflicting literature on the effects of agonists and antagonists, which may partly be due to the lack of selectivity of available drugs, the studies in A 2A receptor knockout mice suggest that A 2A receptor antagonists might have some therapeutic potential in pain states, in particular where high intensity stimuli are prevalent.

show abstract

“…In the current experiments we therefore examined whether SKF 83822 is able to reproduce two of the best established effects of standard D1 receptor agonists, namely the induction of contralateral rotation and the stimulation of expression of immediate-early genes in rats with unilateral dopamine depleting lesions. Most studies of IEG expression have examined only c-fos; under certain conditions, however, various IEGs appear to be differentially expressed (Ons et al, 2004;Pollack and Fink, 1995;Simpson and Morris, 1995). We thus examined the effects of SKF 83822 on the expression of four different IEGs, all of which have been shown to be sensitive to the effects of typical dopamine D1 agonists, in order to increase our chances of detecting unusual aspects of the response to SKF 83822.…”

mentioning

confidence: 99%

Rotation and immediate-early gene expression in rats treated with the atypical D1 dopamine agonist SKF 83822

Wirtshafter

2007

Pharmacology Biochemistry and Behavior

View full text Add to dashboard Cite

Classical agonists of the dopamine D1 receptor activate both adenylyl cyclase and phospholipase C (PLC) signaling pathways. As a result, the extent to which these two pathways are essentially involved in various effects produced by D1 receptor agonists is currently uncertain. In the present report we examined the effects of SKF 83822, a dopamine D1 agonist which has been reported to activate adenylyl cyclase, but not PLC, on behavior and immediate early gene (IEG) expression in rats with unilateral 6-hydroxydopamine lesions. SKF 83822 (25-100 ug/kg) induced dose dependent contralateral rotation in these subjects, and, additionally, stimulated strong expression of the IEG products c-Fos, Fra2, Zif/268 and Arc in the deinnervated striatum. All of these effects could be antagonized by pretreatment with the selective D1 dopamine antagonist SCH 23390 (0.5 mg/kg). Although PLC may be involved in many effects mediated through dopamine D1 receptors, these results suggest that direct activation of PLC is not necessary for the induction of either rotation or IEG expression in dopamine depleted rats.

show abstract

Adenosine antagonists potentiate D2 dopamine-dependent activation of Fos in the striatopallidal pathway

Cited by 92 publications

References 40 publications

Molecular Mechanisms and Therapeutical Implications of Intramembrane Receptor/Receptor Interactions among Heptahelical Receptors with Examples from the Striatopallidal GABA Neurons

Molecular Mechanisms and Therapeutical Implications of Intramembrane Receptor/Receptor Interactions among Heptahelical Receptors with Examples from the Striatopallidal GABA Neurons

Adenosine A2A receptors in ventral striatum, hypothalamus and nociceptive circuitry

Rotation and immediate-early gene expression in rats treated with the atypical D1 dopamine agonist SKF 83822

Contact Info

Product

Resources

About